PAX-D Randomises Its 150th Participant

150 PAX-D Participants have been successfully randomised, meaning they are allocated to either Pramipexole or Placebo treatment

We are pleased to announce that this week the PAX-D trial randomised its 150th participant.

With the recruiting period drawing to a close at the end of the month, we'd like to thank our teams across the country for their superb effort getting as many participants involved in the trial before the deadline. 

We would also like to extend our gratitude to all participants, past or present, for their commitment and contribution to the PAX-D trial.